Wealth Enhancement Advisory Services LLC Increases Stock Holdings in 10x Genomics $TXG

Key Points

• Wealth Enhancement Advisory Services LLC significantly increased its stake in 10x Genomics, raising its holdings by 209.1% to 96,001 shares worth approximately $1.11 million as of the end of the second quarter.
• A range of other institutional investors have also boosted their positions in 10x Genomics, collectively owning 84.68% of the company’s stock.
• Analysts have mixed outlooks on the stock, with price targets ranging from $14.00 to $16.00, and a general average rating of "Hold" among the 15 analysts covering the stock.

Wealth Enhancement Advisory Services LLC grew its position in 10x Genomics (NASDAQ:TXG - Free Report) by 209.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,001 shares of the company's stock after buying an additional 64,940 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.08% of 10x Genomics worth $1,112,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TXG. GAMMA Investing LLC increased its position in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares in the last quarter. Signaturefd LLC increased its position in shares of 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after buying an additional 2,409 shares in the last quarter. Whittier Trust Co. purchased a new stake in 10x Genomics during the 1st quarter worth about $41,000. PNC Financial Services Group Inc. increased its position in 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after purchasing an additional 3,119 shares in the last quarter. Finally, US Bancorp DE increased its position in 10x Genomics by 314.5% during the 1st quarter. US Bancorp DE now owns 5,973 shares of the company's stock worth $52,000 after purchasing an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research report on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Wall Street Zen cut 10x Genomics from a "buy" rating to a "hold" rating in a research report on Saturday, September 13th. Barclays reiterated an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Finally, UBS Group lifted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $13.65.

10x Genomics Trading Up 6.0%

Shares of NASDAQ:TXG opened at $12.39 on Thursday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -17.70 and a beta of 2.06. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $21.47. The stock's 50-day moving average price is $13.23 and its two-hundred day moving average price is $10.97.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the company earned ($0.32) EPS. The company's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is currently owned by corporate insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.